Tekla Capital Management LLC Amicus Therapeutics, Inc. Transaction History

Tekla Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $5.77 Million - $7.31 Million	-587,277 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$8.74 - $11.84 $300,498 - $407,082	-34,382 Reduced 5.53%	587,277 $5.61 Million
Q1 2021 May 14, 2021	BUY	$9.2 - $23.86 $1.99 Million - $5.15 Million	216,033 Added 53.26%	621,659 $6.14 Million
Q3 2020 Nov 13, 2020	BUY	$12.89 - $15.89 $884,795 - $1.09 Million	68,642 Added 20.37%	405,626 $5.73 Million
Q2 2020 Aug 13, 2020	SELL	$8.86 - $15.69 $283,307 - $501,703	-31,976 Reduced 8.67%	336,984 $5.08 Million
Q4 2019 Feb 13, 2020	BUY	$7.48 - $10.75 $406,635 - $584,402	54,363 Added 17.28%	368,960 $3.59 Million
Q1 2019 May 14, 2019	SELL	$10.04 - $13.92 $5.63 Million - $7.81 Million	-560,707 Reduced 64.06%	314,597 $4.28 Million
Q1 2018 May 14, 2018	BUY	$13.76 - $17.12 $3.72 Million - $4.63 Million	270,384 Added 44.7%	875,304 $13.2 Million
Q4 2017 Feb 14, 2018	BUY	$12.51 - $16.24 $4.12 Million - $5.35 Million	329,426 Added 119.58%	604,920 $8.71 Million
Q3 2017 Nov 13, 2017	BUY	$11.74 - $15.78 $1.35 Million - $1.81 Million	114,764 Added 71.4%	275,494 $4.15 Million
Q2 2017 Aug 14, 2017	BUY	N/A	160,730	160,730 $1.62 Million

313

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.78B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.